Potential Cure With $2.1 Million Price Tag Wins U.S. Approval

May 24, 2019, 5:11 PM

A potential cure for a lethal childhood disorder -- the first of its kind in the U.S. -- is hitting the market at a cost of about $2.1 million over five years, paving the way for more therapies that bring dramatic benefits for patients, along with challenges for health-care systems.

The U.S. Food and Drug Administration on Friday approved Novartis AG’s Zolgensma, a gene therapy targeting a severe illness called spinal muscular atrophy. The Swiss drugmaker said it’s offering novel payment options, including spreading out the costs over time, refunds for patients whose treatment fails and discounts for insurers that...

To read the full article log in. To learn more about a subscription click here.